Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6675225 | 0.87 | LMNA (0.56) | LMNASMN1; SMN2ALDH1A1HPGDPGR | |
| SCHEMBL6675713 | 0.84 | LMNA (0.57) | LMNASMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL6675126 | 0.84 | SMN1; SMN2 (0.55) | LMNASMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL6675270 | 0.84 | LMNA (0.52) | LMNASMN1; SMN2ALDH1A1HPGDPGR | |
| SCHEMBL6680003 | 0.81 | LMNA (0.58) | LMNASMN1; SMN2ALDH1A1HPGDPGR | |
| SCHEMBL6680382 | 0.81 | SMN1; SMN2 (0.52) | LMNASMN1; SMN2ALDH1A1HPGDTP53 | |
| SCHEMBL6676918 | 0.81 | ALDH1A1 (0.58) | LMNASMN1; SMN2ALDH1A1HPGDIDH1 | |
| SCHEMBL6673947 | 0.80 | ALDH1A1 (0.56) | LMNASMN1; SMN2ALDH1A1HPGDPGR | |
| SCHEMBL6679367 | 0.80 | ALDH1A1 (0.57) | LMNASMN1; SMN2ALDH1A1HPGDPGR | |
| SCHEMBL6679986 | 0.80 | LMNA (0.48) | LMNASMN1; SMN2ALDH1A1HPGDIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | claimed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | claimed |
| EP-1005453-B1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE LOWERING AGENTS | TULARIK INC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6388131-B2 | Benzenesulfonamide compounds, which encompasses the compound batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene) | TULARIK, INC. | 2002-05-14 | — | — | US | disclosed |
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | disclosed |
| US-6284923-B1 | BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS | TULARIK INC | 2001-09-04 | — | — | US | disclosed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | LMNA 2006/4885SMN1; SMN2 4446/4885ALDH1A1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.